6.56
Astria Therapeutics Inc stock is traded at $6.56, with a volume of 100.28K.
It is down -1.80% in the last 24 hours and up +13.89% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$6.68
Open:
$6.68
24h Volume:
100.28K
Relative Volume:
0.22
Market Cap:
$370.21M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-2.7107
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
+5.13%
1M Performance:
+13.89%
6M Performance:
-11.47%
1Y Performance:
-42.81%
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ATXS
Astria Therapeutics Inc
|
6.56 | 362.31M | 0 | -72.89M | -68.47M | -2.42 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
Jul-29-24 | Initiated | TD Cowen | Buy |
Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
What analysts say about Astria Therapeutics Inc. stockFree Stock Market Forecast Reports - Autocar Professional
What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Astria Therapeutics Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
Published on: 2025-07-19 19:06:02 - jammulinksnews.com
Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser
why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - beatles.ru
What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru
Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha
Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest
Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - BioSpace
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 - BioSpace
Trading (ATXS) With Integrated Risk Controls - news.stocktradersdaily.com
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):